Companion Diagnostics Partnering Terms and Agreements
NEW YORK, Feb. 7, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Companion Diagnostics Partnering Terms and Agreementshttp://www.reportlinker.com/p0362248/Companion-Diagnostics-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics
Report descriptionThe report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1,000 links to online copies of actual companion diagnostics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of companion diagnostic dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading companion diagnostic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of companion diagnostic partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in companion diagnostic partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of companion diagnostic technologies and products.
Key benefits Key benefits• In-depth understanding of companion diagnostics deal trends since 2007
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of companion diagnostics agreements with numerous real life case studies
• Comprehensive access to over 1,000 actual companion diagnostics contracts entered into by the world's biopharma companies
• Detailed access to actual companion diagnostics contracts enter into by the leading fifty bigpharma companies
• Insight into the terms included in a companion diagnostics agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scopeCompanion Diagnostics Partnering Terms and Agreements includes:
o Trends in companion diagnostics dealmaking in the biopharma industry since 2007
o Analysis of companion diagnostics deal structure
o Access to headline, upfront, milestone and royalty data
o Case studies of real-life companion diagnostics deals
o Access to over 1,000 companion diagnostics contract documents
o The leading companion diagnostics deals by value since 2007
o Most active companion diagnostics dealmakers since 2007
o The leading companion diagnostics partnering resources
In Companion Diagnostics Partnering Terms and Agreements, the available contracts are listed by:
o Company A-Z
o Headline value
o Stage of development at signing
o Deal component type
o Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,000 companion diagnostics deals. Analyzing actual contract agreements allows assessment of the following:
o What are the precise companion diagnostics rights granted or optioned?
o What is actually granted by the agreement to the partner company?
o What exclusivity is granted?
o What is the payment structure for the deal?
o How are sales and payments audited?
o What is the deal term?
o How are the key terms of the agreement defined?
o How are IPRs handled and owned?
o Who is responsible for commercialization?
o Who is responsible for development, supply, and manufacture?
o How is confidentiality and publication managed?
o How are disputes to be resolved?
o Under what conditions can the deal be terminated?
o What happens when there is a change of ownership?
o What sublicensing and subcontracting provisions have been agreed?
o Which boilerplate clauses does the company insist upon?
o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
o Which jurisdiction does the company insist upon for agreement law?
Number of pages: The report is comprised of 327 pages. Table of contentsChapter 1 – Introduction
Chapter 2 – Trends in companion diagnostic dealmaking
2.1. Introduction
2.2. Companion diagnostics partnering over the years
2.3. Bigpharma companion diagnostic dealmaking activity
2.4. Bigpharma not active in companion diagnostics
2.5. Companion diagnostic partnering by deal type
2.6. Companion diagnostic partnering by disease type
2.7 Average deal terms for companion diagnostics
2.7.1 Companion diagnostic headline values
2.7.2 Companion diagnostic upfront payments
2.7.3 Companion diagnostic milestone payments
2.7.4 Companion diagnostics royalty rates
Chapter 3 – Leading companion diagnostic deals
3.1. Introduction
3.2. Top companion diagnostic deals by value
3.3. Top companion diagnostic deals involving bigpharma
Chapter 4 – Bigpharma companion diagnostic deals
4.1. Introduction
4.2. How to use bigpharma companion diagnostic partnering deals
4.3. Bigpharma companion diagnostic partnering company profiles
Abbott
Abbott Molecular
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cephalon
CSL
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genzyme
Gilead Sciences
GlaxoSmithKline
GlaxoSmithKline Biologicals
Hospira
Janssen Biotech
Kyowa Hakko Kirin
Lundbeck
Menarini
Mitsubishi Tanabe
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Roche
Roche Diagnostics
Roche Molecular Systems
Genentech
Sanofi
Servier
Shionogi
Stada
Takeda
Teva
Warner Chilcott
Watson
Chapter 5 – Companion diagnostic dealmaking directory
5.1. Introduction
5.2. Company A-Z
5.3. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
5.4. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Development
Distribution
Equity purchase
Evaluation
Grant
Licensing
Manufacturing
Marketing
Option
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
5.5. By therapy area
Cardiovascular
Central nervous system
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hematology
Hormonal disorders
Hospital care
Immunology
Infection
Inflammatory
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Respiratory
Sensory organ
Chapter 6 – Companion diagnostics partnering resource center
6.1. Online companion diagnostics partnering
6.2. Companion diagnostic partnering events
6.3. Further reading on companion diagnostic dealmaking
Appendices
Appendix 1 – Deal type definitions
Appendix 2 – Example companion diagnostic partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Table of figuresFigure 2: Bigpharma – top 50 – companion diagnostic deals 2007 to 2011
Figure 3: Bigpharma companion diagnostic deal frequency – 2007 to 2011
Figure 4: Inactive bigpharma in companion diagnostic 2007-2011
Figure 5: Companion diagnostic partnering by deal type since 2007
Figure 6: Companion diagnostic partnering by disease type since 2007
Figure 7: Companion diagnostic partnering by oncology target since 2007
Figure 8: Companion diagnostic deals with a headline value
Figure 9: Companion diagnostic deal headline value distribution, US$million
Figure 10: Companion diagnostic deal headline value distribution, US$million
Figure 11: Companion diagnostic deals with upfront payment values
Figure 12: Companion diagnostic deal upfront payment distribution, US$million
Figure 13: Companion diagnostic deals with milestone payments
Figure 14: Companion diagnostic deals with royalty rates, %
Figure 15: Top companion diagnostic deals by value since 2007
Figure 16: Top companion diagnostic deals signed by bigpharma value since 2007
Figure 17: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Cardiovascular)
Figure 18: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Central Nervous System)
Figure 19: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Dermatology)
Figure 20: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Gastrointestinal)
Figure 21: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Hematology)
Figure 22: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Hormonal)
Figure 23: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Hospital care)
Figure 24: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Immunology)
Figure 25: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Infectives)
Figure 26:Recent deals (Jan 2007 to Dec 2011) - By therapy area (Inflammatory)
Figure 27: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Metabolic)
Figure 28: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Musculoskeletal)
Figure 29: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Oncology)
Figure 30: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Ophthalmics)
Figure 31: Online partnering resources
Figure 32: Forthcoming partnering events
Figure 33: Deal type definitions
Figure 34: Companion diagnostic partnering agreement between Roche, Rules-Based Medicine, and Psynova Neurotech, December 2009
To order this report:Diagnostics Industry: Companion Diagnostics Partnering Terms and AgreementsMore
Market Research ReportCheck our
Industry Analysis and InsightsCONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article